Serum omentin-1 is correlated with the severity of liver disease in patients with chronic hepatitis C

Table 1 Gender distribution, age, body mass index, model for end stage liver disease score, and laboratory parameters of the 84 patients before therapy start

Parameter	Before therapy	Patients at SVR12
Gender (F/M)	37/47	36/42
BMI kg/m2	26.5 (18.4-40.4)	26.8 (18.4-40.4)
Age yr	56 (24-82)	57 (24-82)
MELD score	7 (6-19)	7 (6-19)
ALT U/L	70 (22-247)	26 (6-135)c
AST U/L	64 (14-1230)	23 (10-1390), n = 76c
Bilirubin mg/dL	1.0 (1.0-4.3)	1.0 (1.0-2.8)
Albumin g/L	37.3 (19.0–45.5), n = 83	39.1 (26.1-47.7)c
INR	1.1 (1.0-2.3)	1.1 (1.0-2.8)
Creatinine mg/dL	1.0 (1.0-1.3)	1.0 (1.0-1.4)
GFR ml/min	98 (47-161)	94 (52–129)
Leukocyte number/L	6.1 (2.2-12.3)	6.2 (1.9-38.6), n = 77
CRP mg/L	2.9 (2.9-29.9)	2.9 (2.9-20.4)
PCT ng/mL	0.08 (0.01–11.02), n = 83	0.04 (0.01-0.15)c
Platelet number/nL	157 (38-364)	171 (38-312), n = 77
HDL mg/dL	52 (19-103), n = 78	51 (23-100), n = 71
LDL mg/dL	91 (31-204), n = 78	117 (38-243), n = 70c

^cP < 0.001.

Data of the 78 patients where serum was available at SVR12 are also listed. In the case that laboratory values were not obtained of all patients, the number (n) of patients of whom these measures were known is given. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; CRP: C-reactive protein; GFR: Glomerular filtration rate; HDL: High density lipoprotein, INR: International normalized ratio; LDL: Low-density lipoprotein; MELD: Model for end stage liver disease; PCT: Procalcitonin.